<DOC>
	<DOCNO>NCT00526175</DOCNO>
	<brief_summary>The purpose study increase efficacy consolidation ( C1 ) intensification phase high dose methotrexate , apply analysis minimal residual disease</brief_summary>
	<brief_title>LAL-BR/2001 : Study Treatment Low Risk ALL</brief_title>
	<detailed_description>REMISION INDUCTION Systemic chemotherapy : Prednisolone ( PDN ) : - 60 mg/m2 day , i.v . p.o. , day 1 27 - 30 mg/m2 day , i.v . p.o. , day 28 35 Vincristine ( VCR ) : 1,5 mg/m2 i.v. , day 8 , 15 , 22 28 . Daunorubicin ( DNR ) : 30 mg/m2 , i.v. , day 8 15 . L-asparaginase ( L-ASA ) : 10.000 UI/m2 , i.m . i.v. , day 9 11 , 16 18 23 25 . Cyclophosphamide ( CFM ) : 1000 mg/m2 , i.v. , day 22 . Intracranial chemotherapy Methotrexate ( MTX ) , cytosine ( ARA-C ) hydrocortisone , day 1 22 CONSOLIDATION TREATMENT ( WEEKS 6 TO 14 ) INTENSIFICACIÃ“N ( C-1 ) - Mercaptopurine ( MP ) 50 mg/m2 , p.o. , day 1-7 , 28-35 56-63 - MTX : 3g/m2 , i.v. , 24 hour , day 1 , 28 56 . - VP-16 : 150 mg/m2 i.v. , day 14-15 42-43 - ARA-C : 1000 mg/m2 i.v. , 3 hour , day 14-15 42-43 - Intrathecal treatment , day 1 , 28 56 . REINDUCTION-CONSOLIDATION TREATMENT ( R-C ) ( WEEKS 15 TO 23 ) Dexamethasone ( DXM ) : - 6 mg/m2 day , p.o. , day 1-21 - 3 mg/m2 day , p.o . i.v. , day 22-28 VCR : 1,5 mg/m2 , i.v. , day 1 , 8 15 DNR : 30 mg/m2 , i.v. , day 1 8 L-ASA : 10.000 UI/m2 i.m . i.v. , day 8 9 , 15 16 , 22 23 . CFM 1000 mg/m2 day , i.v. , day 22 Mercaptopurine ( MP ) 50 mg/m2 , p.o. , day 35-42 MTX : 3g/m2 , i.v. , 24 hour , day 35 . VP-16 : 150 mg/m2 i.v. , day 49-50 ARA-C : 1.000 mg/m2 i.v. , 3 hour , day 49-50 Intrathecal treatment day 1 35 . MAINTENANCE TREATMENT ( M-1 ) Continuous treatment - MP 50 mg/m2/day , p.o . - MTX 20 mg/m2/week , i.m . Reinductions - VCR : 1,5 mg/m2 i.v. , day 1 . - PDN : 30 mg/m2/day , i.v . p.o. , day 1 7 - L-ASA : 20.000 UI/m2 , i.m . i.v. , day 1 . - Intrathecal treatment day 1 Five cycle , week 24 , 30 , 36 , 42 48 . During week administration cycle , continuous chemotherapy suspend . Intrathecal treatment : At start reinduction cycle MAINTENANCE TREATMENT ( M-2 ) ( WEEKS 55-108 ) - MP 50 mg/m2/day , p.o . - MTX 20 mg/m2/week , i.m . - Intrathecal treatment , week 54 108 At end treatment do study MRD ( flux cytometry )</detailed_description>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>6-Mercaptopurine</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Daunorubicin</mesh_term>
	<mesh_term>Asparaginase</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<criteria>Diagnoses low risk acute lymphoblastic leukemia child treat previously Mature BALL ( FABL3 ) cytogenetic ALL `` Burkittlike '' alteration ( [ 8 ; 14 ] , [ 2 ; 8 ] , [ 8 ; 22 ] ) Mixed form ALL Acute Leukemia differentiate Patients coronary disorder , valvular hypertensive cardiopathy Patients chronic liver disorder Chronic pulmonary disorder Renal insufficiency Neurologic disfunction ECOG 3 4 No sign consent form</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>15 Years</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>Acute Lymphoblastic Leukemia</keyword>
	<keyword>Minimal Residual Disease</keyword>
</DOC>